TERAZOSIN

Terazosin Adverse Events Reported to the FDA Over Time

How are Terazosin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Terazosin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Terazosin is flagged as the suspect drug causing the adverse event.

Most Common Terazosin Adverse Events Reported to the FDA

What are the most common Terazosin adverse events reported to the FDA?

Hypotension	248 (8.2%)
Dizziness	237 (7.83%)
Syncope	223 (7.37%)
Orthostatic Hypotension	89 (2.94%)
Fall	80 (2.64%)
Drug Ineffective	48 (1.59%)
Loss Of Consciousness	47 (1.55%)
Asthenia	40 (1.32%)
Headache	40 (1.32%)
Bradycardia	38 (1.26%)
Malaise	34 (1.12%)
	Show More
Nausea	31 (1.02%)
Back Pain	29 (.96%)
Fatigue	28 (.93%)
Abdominal Pain	27 (.89%)
Musculoskeletal Stiffness	26 (.86%)
Drug Interaction	25 (.83%)
Blood Pressure Decreased	24 (.79%)
Dyspnoea	24 (.79%)
Pancreatic Carcinoma	22 (.73%)
Blood Pressure Increased	21 (.69%)
Dehydration	21 (.69%)
Jaundice	21 (.69%)
Diarrhoea	20 (.66%)
Dysuria	20 (.66%)
Presyncope	19 (.63%)
Vision Blurred	18 (.59%)
Completed Suicide	17 (.56%)
Hyperhidrosis	15 (.5%)
Palpitations	15 (.5%)
Head Injury	14 (.46%)
Oedema Peripheral	13 (.43%)
Pneumonia	13 (.43%)
Pollakiuria	13 (.43%)
Rash	13 (.43%)
Renal Failure Acute	13 (.43%)
Muscle Spasms	12 (.4%)
Angina Pectoris	11 (.36%)
Blood Creatinine Increased	11 (.36%)
Chest Pain	11 (.36%)
Feeling Abnormal	11 (.36%)
Joint Swelling	11 (.36%)
Dizziness Postural	10 (.33%)
Oedema	10 (.33%)
Paraesthesia	10 (.33%)
Priapism	10 (.33%)
Treatment Noncompliance	10 (.33%)
Atrial Fibrillation	9 (.3%)
Blood Urea Increased	9 (.3%)
Insomnia	9 (.3%)
Myoclonus	9 (.3%)
Vomiting	9 (.3%)
Arthralgia	8 (.26%)
Benign Prostatic Hyperplasia	8 (.26%)
Cardiac Arrest	8 (.26%)
Chest Discomfort	8 (.26%)
Fibula Fracture	8 (.26%)
Heart Rate Decreased	8 (.26%)
Hypoaesthesia	8 (.26%)
Hypokalaemia	8 (.26%)
Incorrect Dose Administered	8 (.26%)
Medication Error	8 (.26%)
Nocturia	8 (.26%)
Pain In Extremity	8 (.26%)
Sinus Bradycardia	8 (.26%)
Therapeutic Response Unexpected Wit...	8 (.26%)
Tibia Fracture	8 (.26%)
Unevaluable Event	8 (.26%)
Unresponsive To Stimuli	8 (.26%)
Urinary Retention	8 (.26%)
Blood Pressure Diastolic Decreased	7 (.23%)
Condition Aggravated	7 (.23%)
Constipation	7 (.23%)
Drug Dose Omission	7 (.23%)
Drug Intolerance	7 (.23%)
Dysarthria	7 (.23%)
Erectile Dysfunction	7 (.23%)
Heart Rate Increased	7 (.23%)
Hypovolaemia	7 (.23%)
Suicide Attempt	7 (.23%)
Tachycardia	7 (.23%)
Vertigo	7 (.23%)
Weight Increased	7 (.23%)
Blood Pressure Systolic Increased	6 (.2%)
Cardiac Failure	6 (.2%)
Cold Sweat	6 (.2%)
Depression	6 (.2%)
Drug Effect Decreased	6 (.2%)
Drug Hypersensitivity	6 (.2%)
Faeces Discoloured	6 (.2%)
Gait Disturbance	6 (.2%)
Impaired Work Ability	6 (.2%)
Pallor	6 (.2%)
Prostatic Specific Antigen Increase...	6 (.2%)
Renal Failure	6 (.2%)
Rhabdomyolysis	6 (.2%)
Tremor	6 (.2%)
Urinary Incontinence	6 (.2%)
Alanine Aminotransferase Increased	5 (.17%)
Amnesia	5 (.17%)
Aspartate Aminotransferase Increase...	5 (.17%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Terazosin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Terazosin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Terazosin

What are the most common Terazosin adverse events reported to the FDA?

Neurological	602 (19.89%)
Decreased And Nonspecific Blood Pre...	348 (11.5%)
Injuries	129 (4.26%)
Cardiac And Vascular Investigations	101 (3.34%)
Therapeutic And Nontherapeutic Effe...	100 (3.3%)
Cardiac Arrhythmias	95 (3.14%)
Gastrointestinal Signs	86 (2.84%)
Musculoskeletal And Connective Tiss...	76 (2.51%)
Urinary Tract Signs	68 (2.25%)
Respiratory	48 (1.59%)
Electrolyte And Fluid Balance Condi...	46 (1.52%)
	Show More
Medication Errors	46 (1.52%)
Epidermal And Dermal Conditions	45 (1.49%)
Headaches	44 (1.45%)
Joint	37 (1.22%)
Infections - Pathogen Unspecified	33 (1.09%)
Gastrointestinal Motility And Defec...	32 (1.06%)
Renal Disorders	32 (1.06%)
Bone And Joint Injuries	30 (.99%)
Sexual Function And Fertility	30 (.99%)
Vision	30 (.99%)
Muscle	29 (.96%)
Renal And Urinary Tract Investigati...	29 (.96%)
Skin Appendage Conditions	29 (.96%)
Suicidal And Self-injurious Behavio...	28 (.93%)
Lifestyle Issues	25 (.83%)
Gastrointestinal Neoplasms Malignan...	22 (.73%)
Hepatic And Hepatobiliary	22 (.73%)
Sleep Disorders	22 (.73%)
Cardiac Disorder Signs	19 (.63%)
Coronary Artery	18 (.59%)
Physical Examination Topics	16 (.53%)
Procedural And Device Related Injur...	15 (.5%)
Hematology Investigations	14 (.46%)
Prostatic Disorders	13 (.43%)
Arteriosclerosis, Stenosis, Vascula...	11 (.36%)
Glucose Metabolism Disorders	11 (.36%)
Heart Failures	11 (.36%)
Metabolic, Nutritional And Blood Ga...	11 (.36%)
Movement Disorders	11 (.36%)
Vascular	11 (.36%)
Deliria	10 (.33%)
Hepatobiliary	10 (.33%)
Anxiety Disorders	9 (.3%)
Appetite And General Nutritional	9 (.3%)
Bacterial Infectious	9 (.3%)
Upper Respiratory Tract Disorders	9 (.3%)
Allergic Conditions	8 (.26%)
Anemias Nonhemolytic And Marrow Dep...	8 (.26%)
Angiedema And Urticaria	8 (.26%)
Endocrine Investigations	8 (.26%)
Inner Ear And Viiith Cranial Nerve	8 (.26%)
Mental Impairment	8 (.26%)
Neurological, Special Senses And Ps...	8 (.26%)
Ocular Structural Change, Deposit A...	8 (.26%)
Peripheral Neuropathies	8 (.26%)
Product Quality Issues	8 (.26%)
Tendon, Ligament And Cartilage	8 (.26%)
Water, Electrolyte And Mineral	8 (.26%)
Body Temperature Conditions	7 (.23%)
Breast	7 (.23%)
Central Nervous System Vascular	7 (.23%)
Depressed Mood Disorders	7 (.23%)
Immunology And Allergy	7 (.23%)
Platelet	7 (.23%)
White Blood Cell	7 (.23%)
Bladder And Bladder Neck Disorders	6 (.2%)
Demyelinating	5 (.17%)
Lower Respiratory Tract Disorders	5 (.17%)
Musculoskeletal And Connective Tiss...	5 (.17%)
Salivary Gland Conditions	5 (.17%)
Therapeutic Procedures And Supporti...	5 (.17%)
Adrenal Gland	4 (.13%)
Anterior Eye Structural Change, Dep...	4 (.13%)
Bronchial Disorders	4 (.13%)
Chemical Injury And Poisoning	4 (.13%)
Disturbances In Thinking	4 (.13%)
Eye	4 (.13%)
Fatal Outcomes	4 (.13%)
Fungal Infectious	4 (.13%)
Gastrointestinal Conditions	4 (.13%)
Gastrointestinal Inflammatory Condi...	4 (.13%)
Hematological And Lymphoid Tissue T...	4 (.13%)
Hepatobiliary Therapeutic Procedure...	4 (.13%)
Miscellaneous And Site Unspecified ...	4 (.13%)
Myocardial	4 (.13%)
Neurological Disorders Of The Eye	4 (.13%)
Ocular Hemorrhages And Vascular	4 (.13%)
Psychiatric	4 (.13%)
Respiratory And Pulmonary Investiga...	4 (.13%)
Seizures	4 (.13%)
Sleep Disturbances	4 (.13%)
Vascular Hypertensive	4 (.13%)
Connective Tissue Disorders	3 (.1%)
Enzyme	3 (.1%)
Gastrointestinal Ulceration And Per...	3 (.1%)
Mood Disorders	3 (.1%)
Respiratory And Mediastinal Neoplas...	3 (.1%)
Abdominal Hernias And Other Abdomin...	2 (.07%)
Exocrine Pancreas Conditions	2 (.07%)
Gallbladder	2 (.07%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Terazosin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Terazosin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.